Hardman Johnston Global Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.2M Sell
289,606
-27,164
-9% -$2.24M 1.1% 23
2025
Q4
$27M Sell
316,770
-34,124
-10% -$2.8M 1.29% 22
2025
Q3
$27.3M Sell
350,894
-60,699
-15% -$4.74M 1.34% 23
2025
Q2
$32.2M Buy
411,593
+115,822
+39% +$8.64M 1.43% 24
2025
Q1
$21.4M Sell
295,771
-2,315
-0.8% -$166K 1.02% 32
2024
Q4
$22.1M Sell
298,086
-7,170
-2% -$502K 0.91% 33
2024
Q3
$20.1M Sell
305,256
-10,315
-3% -$749K 0.79% 32
2024
Q2
$29.1M Sell
315,571
-10,610
-3% -$940K 1.13% 27
2024
Q1
$31.2M Sell
326,181
-1,790
-0.5% -$150K 1.08% 30
2023
Q4
$25M Sell
327,971
-3,455
-1% -$240K 0.8% 33
2023
Q3
$23M Sell
331,426
-3,790
-1% -$305K 0.77% 35
2023
Q2
$31.6M Sell
335,216
-8,196
-2% -$712K 1.03% 32
2023
Q1
$28.4M Sell
343,412
-207,316
-38% -$16.3M 0.93% 35
2022
Q4
$41.1M Sell
550,728
-121,470
-18% -$9.36M 1.61% 21
2022
Q3
$55.5M Buy
672,198
+65,404
+11% +$6.29M 2.5% 13
2022
Q2
$57.7M Sell
606,794
-6,430
-1% -$666K 2.45% 10
2022
Q1
$72.2M Sell
613,224
-57,430
-9% -$6.44M 2.32% 11
2021
Q4
$86.9M Sell
670,654
-18,520
-3% -$2.16M 2.34% 12
2021
Q3
$78M Sell
689,174
-55,420
-7% -$6.33M 2.1% 13
2021
Q2
$77.1M Buy
744,594
+35,325
+5% +$3.33M 1.87% 12
2021
Q1
$59.3M Sell
709,269
-2,360
-0.3% -$200K 1.69% 14
2020
Q4
$64.9M Sell
711,629
-6,160
-0.9% -$511K 1.88% 11
2020
Q3
$57.3M Buy
717,789
+41,135
+6% +$3.21M 2.14% 10
2020
Q2
$46.8M Buy
676,654
+4,780
+0.7% +$340K 2.06% 13
2020
Q1
$42.2M Buy
671,874
+4,140
+0.6% +$299K 2.46% 12
2019
Q4
$51.9M Sell
667,734
-31,824
-5% -$2.48M 2.1% 14
2019
Q3
$51.3M Sell
699,558
-128,220
-15% -$9.01M 2.35% 12
2019
Q2
$51M Sell
827,778
-60,420
-7% -$3.65M 2.26% 12
2019
Q1
$56.6M Sell
888,198
-82,875
-9% -$4.73M 2.49% 10
2018
Q4
$49.6M Sell
971,073
-55,500
-5% -$2.81M 2.57% 10
2018
Q3
$59.6M Sell
1,026,573
-13,560
-1% -$663K 2.57% 9
2018
Q2
$50.5M Sell
1,040,133
-81,390
-7% -$3.8M 2.13% 9
2018
Q1
$52.2M Sell
1,121,523
-15,330
-1% -$666K 2.22% 8
2017
Q4
$42.7M Sell
1,136,853
-4,560
-0.4% -$167K 1.81% 15
2017
Q3
$41.6M Buy
1,141,413
+3,360
+0.3% +$128K 1.77% 14
2017
Q2
$44.9M Buy
1,138,053
+122,550
+12% +$4.47M 1.94% 9
2017
Q1
$31.8M Sell
1,015,503
-1,626
-0.2% -$50.9K 1.43% 18
2016
Q4
$31.8M Sell
1,017,129
-8,733
-0.9% -$283K 1.55% 17
2016
Q3
$41.2M Sell
1,025,862
-55,164
-5% -$2.08M 1.88% 11
2016
Q2
$35.9M Sell
1,081,026
-23,610
-2% -$808K 1.83% 12
2016
Q1
$32.5M Buy
1,104,636
+10,446
+1% +$288K 1.91% 13
2015
Q4
$28.8M Buy
1,094,190
+87,750
+9% +$2.28M 1.91% 16
2015
Q3
$23.8M Buy
1,006,440
+73,920
+8% +$1.78M 1.59% 22
2015
Q2
$22.1M Sell
932,520
-21,480
-2% -$485K 1.33% 27
2015
Q1
$22.7M Buy
954,000
+1,620
+0.2% +$36.3K 1.37% 27
2014
Q4
$20.2M Sell
952,380
-42,000
-4% -$844K 1.09% 35
2014
Q3
$16.9M Sell
994,380
-9,540
-1% -$151K 0.94% 36
2014
Q2
$14.4M Buy
1,003,920
+12,840
+1% +$174K 0.77% 41
2014
Q1
$12.3M Buy
991,080
+28,722
+3% +$331K 0.72% 44
2013
Q4
$10.5M Buy
962,358
+264,840
+38% +$2.99M 0.69% 45
2013
Q3
$8.1M Buy
697,518
+1,260
+0.2% +$14.7K 0.54% 46
2013
Q2
$7.8M Buy
+696,258
New +$8.24M 0.53% 45

Other funds holding EW

Hardman Johnston Global Advisors's EW Position: Q1 2026 in Review

Hardman Johnston Global Advisors reduced its Edwards Lifesciences (EW) stake by 8.6% in Q1 2026, selling an estimated $2.24M and leaving 289,606 shares worth $23.2M. The position accounts for 1.1% of the portfolio, ranked #23.

Hardman Johnston Global Advisors first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $86.9M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Hardman Johnston Global Advisors held 289,606 shares of Edwards Lifesciences worth $23.2M as of Q1 2026.
  • Hardman Johnston Global Advisors sold 27,164 Edwards Lifesciences shares in Q1 2026, an estimated $2.24M.
  • Edwards Lifesciences made up 1.1% of Hardman Johnston Global Advisors's portfolio in Q1 2026, its #23 holding.
  • Hardman Johnston Global Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Hardman Johnston Global Advisors's Edwards Lifesciences position peaked at $86.9M in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Hardman Johnston Global Advisors's 13F filing for Q1 2026, filed 13 May 2026.